Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Journal: JCO oncology practice
Published: July 19, 2024
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 19, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 28, 2023
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Journal: Cancers
Published: August 27, 2022
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
Journal: Cancer treatment reviews
Published: March 11, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Journal: Cancer discovery
Published: March 11, 2021
Neoadjuvant breast cancer therapy and drug development.
Journal: Clinical advances in hematology & oncology : H&O
Published: April 09, 2016
Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives.
Journal: Oncology (Williston Park, N.Y.)
Published: November 18, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 19, 2015
Pathological complete response in breast cancer--authors' reply.
Journal: Lancet (London, England)
Published: February 24, 2015
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2014
Last Updated: 09/26/2026